Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage

Pietro Carotenuto1,2,12, Francesco Amato3,12, Andrea Lampis4,12, Colin Rae3, Somaieh Hedayat4, Maria C. Previdi1, Domenico Zito4, Maya Raj1, Vincenza Guzzardo5, Francesco Sclafani6, Andrea Lanese6, Claudia Parisi6, Caterina Vicentina7, Ian Said-Huntingford1, Jens C. Hahne4, Albert Hallsworth1, Vladimir Kirkin1, Kate Young6, Ruwaida Begum6, Andrew Wotherspoon6, Kyriakos Kouvelakis6, Sergio Xavier Azevedo6, Vasiliki Michalarea6, Rosie Upstill-Goddard3, Sheela Rao6, David Watkins6, Naureen Starling6, Anguraj Sadanandam4, David K. Chang3,8, Andrew V. Biankin3,8,9, Nigel B. Jamieson3,8, Aldo Scarpa7, David Cunningham6, Ian Chau6, Paul Workman1, Matteo Fassan5,10, Nicola Valeri4,6 & Chiara Braconi1,3,6,11

FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan-FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. In this study we explore the role of miRNAs (MIR) as modulators of chemosensitivity to identify potential biomarkers of response. We find that 41 and 84 microRNA inhibitors enhance the sensitivity of Capan1 and MiaPaCa2 PDAC cells respectively. These include a MIR1307-inhibitor that we validate in further PDAC cell lines. Chemotherapy-induced apoptosis and DNA damage accumulation are higher in MIR1307 knock-out (MIR1307KO) versus control PDAC cells, while re-expression of MIR1307 in MIR1307KO cells rescues these effects. We identify binding of MIR1307 to CLIC5 mRNA through covalent ligation of endogenous Argonaute-bound RNAs cross-linking immunoprecipitation assay. We validate these findings in an in vivo model with MIR1307 disruption. In a pilot cohort of PDAC patients undergoing FOLFIRONX chemotherapy, circulating MIR1307 correlates with clinical outcome.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a survival rate lower than 10% at 5 years and a median overall survival (OS) of less than 12 months in metastatic patients. Systemic treatment for PDAC has been limited to gemcitabine monotherapy for many years. More recently, novel combination approaches have led to an improvement in response rate (RR) and OS. FOLFIRINOX is a three-drug regime that increases RR compared to gemcitabine (32 vs 9%) but is associated with more severe toxicity. The remarkable RR achieved with FOLFIRINOX has led to the introduction of this chemotherapy in the neo-adjuvant setting. Despite FOLFIRINOX being reserved to patients with good performance status in current clinical practice, no evidence suggests that this parameter can predict sensitivity. In addition, the
controls play a key role in promoting pancreatic carcinogenesis and can act by controlling post-transcriptional regulation of mRNA. MIR markers able to predict the benefit from FOLFIRINOX in PDAC patients are eagerly warranted. Genetic biomarkers have shown some promise in predicting benefit from monoclonal-antibodies or tyrosine-kinase inhibitors; however, they have not proven useful to predict response to conventional chemotherapy. Growing evidence suggests that the non-protein-coding portion of the genome is crucial for cell homeostasis, carcinogenesis, and drug response. Several classes of non-coding RNAs (ncRNAs) have been identified; among these, microRNAs (miRNAs or MIR) are short (18–22nt) ncRNAs that act by controlling post-transcriptional regulation of mRNA. miRNAs play a key role in promoting pancreatic carcinogenesis and can aid differentiation of pancreatic cancer patients from healthy controls. In the current study, by using a high-throughput genome-wide approach exploring the functional role of miRNAs in pancreatic cancer cells exposed to chemotherapy, we identify the role of MIR1307 in mediating chemoresistance to FOLFIRINOX and propose its use as a biomarker of response to this chemotherapy regimen.

**Results**

High-throughput screening with microRNA inhibitors in PDAC cell lines. We performed a functional genome-wide high-throughput screening (HTS) of ~1000 Locked Nucleic Acid (LNA) MIR inhibitors in human PDAC cells treated with a combination of fluorouracil (F), oxaliplatin (O), and irinotecan (I) that resembles the FOLFIRINOX regimen in vitro. Based on the Growth Inhibitory (GI)₅₀ concentration of single compounds (Supplementary Fig. S1A), we selected concentrations of the three drugs that, in combination (FOI), could reproducibly reduce cell viability of PDAC cells by no more than 50% to allow identification of sensitizers (Supplementary Fig. S1B, C). HTS was performed in human PDAC Capan1 and MiaPaCa2 cell lines in triplicate. Forty-one and 84 MIR inhibitors were able to increase chemosensitivity by >30% (p < 0.001) in both the cell lines are shown. The validation of selected HTS hits was performed in a panel of PDAC cell lines with different inhibitory probes (mirVana microRNA inhibitors, ThermoFisher Scientific) following the same protocol used for HTS. Cells were transfected with the indicated probes and then treated with FOI for 72 h. Bars indicate mean and standard deviation (SD) of five replicates. p values from two-sided t-test are reported. PDAC cell lines were transfected with MIR inhibitors mirVana microRNA inhibitors, ThermoFisher Scientific while they were treated with DMSO or FOI for 48 h. Bars indicate the LOG value of the ratio between FOI and DMSO and are presented normalized to NEG CTRL. Bars below the 0 line indicate that cell viability was reduced by the MIR inhibitor in the FOI treated vs the DMSO treated cells, indicating specificity for chemotherapy. MIR1307 expression was assessed by Taqman assay in the tumour (TT) and adjacent tissue (AT) of 59 human PDAC samples (cohort 1). Dots represent log of the ratio between the expression in TT and that in AT for each patient. Dashed lines indicate TT > AT fold change >1.3. MIR1307 was assessed by in situ hybridization in FFPE tissue from human resected PDAC. Representative pictures of four different cases of PDAC. Bars indicate 100 μm. In the bottom left quadrant, it is possible to observe positive epithelial cancer cells (black square) and negative normal ducts (right of the dashed line). MIR1307 expression was assessed in human PDAC cell lines by Taqman assay. Bars represent the mean and SD of three replicates. G MIR1307KO and WT MiaPaCa2 cells were treated with oxaliplatin (scalar concentrations as indicated in the figure) or vehicle for 48 h. Bars represent the LOG value of the ratio between drug and vehicle and are presented normalized to WT. Bars below the 0 line indicate that the reduction in cell viability was increased in MIR1307KO cells. Purple bars indicate statistically significant (p < 0.05). Bars indicate mean and SD of five replicates. Cell viability was reduced by 75% at the highest dose in WT. 5-Fluorouracil (see above). Cell viability was reduced by 69% at the highest dose in WT. Bars indicate mean and SD of five replicates. I Irinotecan (see above). Cell viability was reduced by 93% at the highest dose in WT. Bars indicate mean and SD of five replicates. J Gemcitabine (see above). Cell viability was reduced by 60% at the highest dose in WT. Bars indicate the mean and SD of five replicates. K Olaparib (see above). Cell viability was reduced by 50% at the highest dose in WT.
in a dose-dependent fashion in MIR1307KO in comparison to wild-type (WT) MiaPaCa2 cell lines (Supplementary Fig. 3G, H). When the drugs were used separately, disruption of MIR1307 changed sensitivity to oxaliplatin and partially to fluorouracil (Fig. 1G, H), while no effects were recorded for irinotecan (Fig. 1I), suggesting that the activity is likely related to platinum DNA damage response. Indeed, MIR1307KO cells were confirmed to be more sensitive to olaparib, but not to gemcitabine (Fig. 1J, K). Combined FOI chemotherapy for 48 h reduced cell viability by 40% in MIR1307KO MiaPaca2 cells (Fig. 2A). Clonogenic survival assay confirmed a long-term effect of MIR1307 on chemotherapy sensitivity (Fig. 2B).

In line with these data MIR1307KO cells were more prone to undergo apoptosis than control cells when treated with staurosporin...
Fig. 2 MIR1307 disruption increases apoptosis in PDAC cells. A MIR1307KO and WT MiaPaca2 cells were treated for 48 h with FOI or DMSO and cell viability assessed by CellTiter Blue. Values from two-sided t-test are reported. B MIR1307KO and WT cells were plated and treated with FOI and DMSO for 10 days before being stained with Crystal Violet. Representative pictures (left) and quantification of four replicates with standard deviation (right) are presented. Values from two-sided t-test are reported. C Activation of caspase 3/7 was measured by luminescence after 24 h of treatment with staurosporin. Bars represent the mean and SD of six replicates. Values from two-sided t-test are reported. D Cells were treated with DMSO or FOI for 48 h before activation of caspase 3/7 activity was measured by luminescence. Staurosporin (10 μM) was added as positive control. Bars indicate the mean and SD of six replicates. Values from two-sided t-test are reported. E Positivity for Annexin V was measured by flow cytometry after 24, 48, and 72 h of treatment. Bars represent the mean and SD of three replicates. Values from two-sided t-test are reported. F Cells were treated with DMSO or FOI for 48 h in association with vehicle or Z-VAD (caspase inhibitor) 10 μM. Source data are provided as a Source Data file. G Cells were plated in 96 well plates and treated with the indicated drugs for 48 h, after which caspase 9 activation was assessed by caspase 9 GLO9 assay. Increasing doses of FOI (from 0.5 to 10 μM) were used, while FFCP (10 μM), H2O2 (300 μM) and staurosporin (10 μM) were used as activators of the intrinsic apoptosis. Bars indicate the mean and SD of three replicates. * indicates p < 0.05 from two-sided t-test are reported.

CLIC5 as a mediator of MIR1307 effects. In order to gain insights into the mechanism of action of MIR1307, we performed CLEAR-CLIP of the RNA-binding protein Argonaute to decode the CLEAR-CLIP29 of the RNA-binding protein Argonaute to decode (Fig. 3G). Rescued expression of MIR1307 in MIR1307KO cells (Fig. 3B), DNA breaks (Fig. 3C) and the highest changes were confirmed by real time PCR (Fig. 3D) and Western Blot (Supplementary Figs. 4 and 5A). We mapped 5 MIR1307-mRNA chimeras in the WT cells that were not detected in MIR1307KO: these included Chloride Intracellular Channel 5 (CLIC5), Integrin Subunit Alpha 1 (ITGAI), Ras-Related Protein Rab-8A (RAB8A), Stanniocalcin-2 (STC2) and Sytinx 11 (STX11) but only CLIC5 and STC2 were detected at a meaningful read number (above 200 reads/million total reads) (Supplementary Table 3). Changes in mRNA expression for these genes were assessed by real time PCR (Fig. 5A) and the highest changes were confirmed to be recorded for CLIC5 and STC2. CLIC5 is a member of a family of chloride channels, which form redox and pH-sensitive ion channels and have been involved in cancer progression and chemoresistance.30 A pro-apoptotic role for mitochondrial CLICs has also been suggested.31 Specifically, CLIC5 is found in the inner membrane of the mitochondria, where the electron exchange occurs. Deregulation of this exchange leads to generation of superoxide which damage mitochondrial DNA (mtDNA) and nuclear DNA.32 Indeed, chemoresistance is affected by mitochondrial activity, either via direct effect from the mtDNA or via exhaustion of cells’ antioxidant capacity which activates apoptosis.32 The CLEAR-CLIP sequencing data identified a binding site for MIR1307 in the CLIC5 coding sequence (CDS) (Supplementary Fig. 5B), which is conserved across species. In line with the hypothesis that CLIC5 may represent a mRNA target for MIR1307, CLIC5 mRNA expression was found to be significantly increased in MIR1307KO cells compared to WT, while its protein expression was down-regulated by the enforced expression of MIR1307 (Fig. 5B, C). MIR1307 was found to directly interact with CLIC5 within the binding site identified by the CLEAR-CLIP as shown by luciferase assays (Fig. 5D). Expression of CLIC5 protein was inversely related to MIR1307 expression in human PDAC tissues (Supplementary Fig. 5C). Downregulation of CLIC5 in MIR1307KO cells reproduced the functional effect on chemoresistance that was induced by enforced re-expression of MIR1307 (Fig. 5E). In addition, the effect on DNA damage accumulation by MIR1307 disruption was rescued by the inhibition of CLIC5 in MIR1307KO cells exposed to FOI chemotherapy (Fig. 5F, G). To investigate the role of MIR1307-CLIC5 in Reactive Oxygen Species (ROS) generation we measured the levels of ROS in WT and MIR1307KO cells after transfection with siCLIC5 and siCTRL while cells were treated with and without N-acetyl-cysteine (NAC), a ROS inhibitor. We observed an increased ROS generation in MIR1307KO cells, which was remarkably enhanced after 24 h of FOI treatment. This finding was rescued by inhibition of CLIC5 in MIR1307KO cells, suggesting that MIR1307 mediates ROS generation via CLIC5 (Fig. 5H). CLIC5 expression was found downregulated in the squamous subtype vs the progenitor subtypes (adjusted p<0.02) in the ICGC (International Cancer Genome Consortium) cohort, in line with the data on response to FOLFIRINOX in the COMPASS study (Supplementary Fig. 5D).

Validation of the effects of MIR1307 inhibition in another PDAC cell line. To validate our findings, we studied the functional effect of MIR1307 silencing in another PDAC cell line. Capan 1 cells were stably infected via a lentiviral vector to express an anti-MIR1307 short hairpin (miRZip MIR1307-sh) or a scrambled probe (miRZip CTRL) (Fig. 6A). CLIC5 mRNA and protein expression was increased in Capan1 miRZip MIR1307-sh compared to miRZip CTRL (Fig. 6B, C). Capan1 miRZip MIR1307-sh cells were more sensitive to FOI than miRZip CTRL cells (Fig. 6D), had increased apoptosis at 48 h (Fig. 6E), and displayed increased DNA damage as shown by the COMET assay (Fig. 6F). We observed increased staining of ATM and pH2AX at 24 h in miRZip MIR1307-sh compared to miRZip CTRL (Fig. 6G).

In vivo validation of the role of MIR1307 in chemoresistance. When MiaPaca MIR1307KO and WT tumour xenografts were treated with FOI or vehicle control, we observed activity of FOI chemotherapy in both groups, but the response was more durable in the MIR1307KO compared to WT group, suggesting that the DNA damage repair (DDR) is limited in the tumours lacking MIR1307 (Fig. 7A–C and Supplementary Table 4). No statistically significant differences in tumour growth were noted between WT and MIR1307KO mice in absence of FOI treatment until 21 days post-inoculation, even though the tumour growth appeared slower in
MIR1307KO. However, changes in tumour growth between MIR1307KO and WT were enhanced in the FOI-treatment arm. Although we cannot exclude an effect of MIR1307 on tumour growth, our data support an effect of MIR1307 on FOI resistance. In line with these data, we detected statistical significant tumour shrinkage only in MIR1307KO mice treated with FOI (Fig. 7B). In addition, the weight of excised tumours in FOI-treated mice was reduced by 25 and 41% in comparison to vehicle in WT and MIR1307KO groups respectively (Fig. 7C). Expression of markers of DNA damage was increased in MIR1307KO tumour xenografts compared to WT. In line with our in vitro data, MIR1307 disruption makes tumours more prone to undergo DNA damage in vivo as highlighted by the high pH2Ax (Fig. 7D) and caspase 3 (Fig. 7E) in FOI-treated MIR1307KO xenografts compared to WT. Last, we
verified the potential of MIR1307 to be used as a biomarker of response to FOLFIRINOX chemotherapy in patients undergoing first line palliative treatment. Patients with unresectable PDAC treated with FOLFIRINOX were retrieved from the SSCCG (Screening Study of Genetic Changes in Colorectal, Gastrointestinal and Hepatobiliary Cancers) study, which allowed collection of clinically annotated baseline pre-treatment plasma samples (Supplementary Table 5). Analysis of circulating MIR1307 was performed in these samples by digital droplet PCR. High expression of circulating MIR1307 was associated with reduced benefit from FOLFIRINOX chemotherapy in inoperable PDAC patients (Fig. 8) and was independent from disease stage (p:0.81) and performance status (p:0.58).
Discussion
FOLFIRINOX is a three-drugs combination regimen that is widely used in the clinical management of PDAC patients. In the adjuvant setting, FOLFIRINOX has provided a significant benefit over gemcitabine with a 20-month increase in median overall survival and a 20% reduction in tumour recurrence at 3 years. In advanced unresectable PDAC, FOLFIRINOX represents the most effective chemotherapy regimen with a response rate > 30%. Preliminary data from the ESPAC5 trial also suggested a possible role for neoadjuvant FOLFIRINOX in improving survival rate of resectable PDAC patients. Despite these exciting results, FOLFIRINOX is still reserved to a minority of patients due to the severe toxicity profile with up to 75% of patients experiencing grade 3 or 4 side effects. These data underline the need for biomarkers that support a...
programme of advanced supportive care to improve tolerability in patients who derive benefit from FOLFIRINOX, while sparing unnecessary toxicities to non-responders. Despite remarkable advancement in the field of biomarker development, most of the successes have been recorded for the identification of targetable molecular alterations that predict the benefit to targeted therapies. Unfortunately, no biomarkers have yet been identified to personalize cytotoxic chemotherapy delivery in a scenario where more and more regimens are becoming available. Whole transcriptomic profiles delineated signatures of homologous recombination pathways that are associated with platinum response in vitro in human PDAC cell lines. DDR gene mutations have been associated with FOLFIRINOX response in retrospective cohorts of PDAC patients. These analyses require appropriate tissue quantity and quality for DNA analyses.

In our study, we provide an additional liquid biopsy test that can be widely applicable and cost-effective to select FOLFIRINOX responders and deserve clinical investigation in PDAC patients. Functional biological high-throughput analyses have been applied in this work to explore the role of MIRs in the dynamics of drug response in live human PDAC cells exposed to FOLFIRINOX chemotherapy. The advantage of this approach over descriptive comparative analyses in sensitive vs resistant models relies on the possibility to unmask responsive mechanisms of chemoresistance that occur in (1) living cells under treatment stress and (2) in subclones of chemoresistant cells. Indeed, in biliary cancers, we have previously shown that chemotherapy resistance is based on a functional response of a subclone population, whose growth and activity would be masked from descriptive analyses. Our choice of investigating MIRs inhibitors as mediators of chemoresistance is based on (1) the potential of circulating MIRs to be detected in patients’ plasma through non-invasive tests, (2) the greater accuracy of detecting the presence (rather than absence) of circulating MIRs in human blood samples, and (3) the association between circulating and tissue MIRs. Through these studies, we identified a promising microRNA, MIR1307, which mediates chemoresistance in vitro and in vivo and reflects clinical benefit in a pilot cohort of advanced PDAC patients. From a clinical perspective, these data warrant further investigation and assessment in prospective clinical studies. Our study indicates feasibility to detect and quantitate circulating MIR1307 RNA copies, thus providing potential quantitative threshold for prospective assessment. Based on our biological data the action of MIR1307 seems to be related to platinum DNA damage. Indeed, modulation of MIR1307 expression affects mainly sensitivity to platinum-containing regimens. We observed MIR1307 to alter the expression of CLIC5. CLIC5 is known to be involved in ion transport through cellular compartments. Proteins of the CLIC family are regulated by cytoskeleton filaments and modify solute transport (not only chloride) during biological processes such as apoptosis. CLIC4 and CLIC5 are the only members of the family to be expressed in the mitochondrial membrane, with CLIC4 being detected in the outer membrane and CLIC5 being abundant in the inner mitochondrial membrane. Mitochondria harbour a plethora of regulated ion channels whose function is related to ion/metabolite transport and to fine-tuning of mitochondrial membrane potential, as well as of reactive oxygen species release. Alterations in mitochondrial DNA were shown to result in chemoresistance and may constitute the link between deregulation of MIR1307 and drug resistance. Indeed, CLIC4 was found to be reduced in cancer cells and have onco-suppressive properties, and low CLIC5 expression seems to be associated with poor prognosis in breast cancer patients. We observed a higher expression of CLIC5 in the classical subtype compared to the squamous subtype. Data from the COMPASS trial looking at molecular biomarkers in PDAC patients undergoing FOLFIRINOX clearly showed that response rate was significantly greater in the classical subtype compared to the basal-like (34% vs 8%). These findings support our data that the MIR1307-induced reduction of CLIC5 may be responsible for FOLFIRINOX resistance in the squamous (basal-like) subtype.

Lastly, we would like to draw attention to a new methodology; in this study, we employed an adapted version of CLEAR-CLIP described by Moore et al. The use of RNA chimeras provides the advantage of identifying UV crosslinked AGO-miRNA-mRNA complexes bound in a single dataset. However, as with the traditional HTIS-CLIP method, it requires the use of radioisotope labelling of RNAs at 5′ ends making its application limited to specific labs with dedicated areas. Moreover, the natural decay of radioactive reagents reduces the signal in autoradiography, making it difficult to optimize across experiments. Here we confirm that the use of fluorescent probes can retain stable signal in time and can be handled in any lab, enhancing the potential wide use of the method for inter-lab cross-comparison of results.

**Methods**

**Cell line.** PDAC cell lines were purchased from the American Type Culture Collection. Cells were regularly tested negative for Mycoplasma and authenticated through Short Tandem Repeat (STR) analysis. All cancer cells were cultured in Dulbecco’s Modified Eagle Media with 10% fetal bovine serum (ThermoFisher Scientific, UK), at 37 °C with 5% carbon dioxide.
Cell viability. Cell viability was measured by CellTiter-Blue® Assay (Promega, Madison, WI, USA) and the GI50 derived using Prism Software (Graphpad, La Jolla, USA).

High-throughput-screening (HTS). A human LNA MIR inhibitor library (miRCURY LNA, version 3) from Exiqon (Qiagen, UK) was purchased. The library was distributed across 5 × 384-well plates (Greiner Bio-One, Frickenhausen, Germany). Each plate included two negative controls (LNA negative A, LNA negative B from Exiqon; each in quadruplicate), a positive control in quadruplicate (siTOX from Dharmacon Lafayette, Colorado, USA). Additional controls for each plate were: mock controls (quadruplicates), only medium (quadruplicate), and no cells (× 20). Transfecting solution with medium and Dharmafect (Dharmacon, Lafayette, Colorado, USA) was added to the central wells of 384-well plates; MIR inhibitors were added by dispensing 500 nL solution from a source plate containing the inhibitors at a concentration of 5 μM in PBS, into the central 320 wells of a 384-plate. Thirty μl of cell solution was then added to each well to have a final concentration of 1000 cells and 50 nM of MIR inhibitors per well. Forty-eight hours
Fig. 6 Validation of MIR1307-mediated effect in an independent in vitro PDAC model. A Can-1 cells were stably infected with miRZip lentiviral vectors expressing MIR1307-sh or CTRL probes. MIR1307. A miRZip MIR1307-sh cells had reduced MIR1307 expression when detected by Taqman assay. Please note that it is recognized that Taqman assays can detect the MIR1307-sh produced by the vector and therefore justifies the lack of >90% MIR1307 expression. Bars represent mean of three biological replicates with SD. Values from two-sided t-test are reported. B CLIC5mRNA was assessed by real-time PCR. Bars represent the mean and SD of three biological replicates. Values from two-sided t-test are reported. C CLIC5 and vinculin protein expression were assessed by western blotting. D Cells were plated in 96-well plates and treated with DMSO or FOI for 48 h before assessing cell viability by CellTiterBlue. Bars represent the mean and SD of 12 replicates repeated in two separate occasions. Values from two-sided t-test are reported. E Can-1 cells were treated with serial concentrations of FOI (from 0.5 to 10 μM) in presence of absence of caspase 9 inhibitor for 48 h before being assessed for caspase activation. Bars represent the mean and SD of three independent replicates. F Can-1 cells were treated for 48 h and COMET assay performed afterwards. Representative images are shown (magnification scale 20×, magnification bar indicates 50 μm). At least 50 cells (across three replicates) were assessed for each sample. G Cells were treated with DMSO or FOI for 24 h and fixed before being stained with the indicated fluorescent antibodies. Representative pictures (left) along with quantitation (right) of the percentage of positive cells on the total cells in the field, with at least five fields assessed per replicate in six biological replicates. Bars represent the mean and 95% confidence interval. The magnification bar indicates 20 μm.

later, compounds were added by dispensing 125 nL compound solution from a source plate containing the compounds at a concentration of 4 μM (fluorouracil), 4 μM (oxaliplatin), and 2 μM (mitomycin c in 3% DMSO). Cell viability was measured 48 h later by CellTiter-Blue® Assay (Promega, Madison, WI, USA). The cell viability measurement from each hit was normalized to that of the averaged negative controls across five plates. Each cell line was tested in triplicate. Statistical significance (p < 0.05) was determined by two-sided t-test across three replicates.

Validation experiments. The same protocol used for the HTS was used for the validation experiments. However, mirVana inhibitors probes were used (Life Technologies, Paisley, UK), and cells were treated either with a combination of chemotherapy (FOI) or with 10% DMSO.

Human tissues. The human PDAC tissues were collected under the approval of the Ethical Committee for Clinical Research at the Royal Marsden NHS Trust (Panther study: CCR 4192). All tissues were collected with informed consent. Formalin-fixed paraffin-embedded (FFPE) tissues were recovered from 60 early PDAC that underwent resection between 1999 and 2015. RNA was extracted from a subcutaneous tumor for the in situ hybridization. The corresponding FFPE sections were used for the validation experiments. However, mirVana inhibitors probes were used (Life Technologies, Paisley, UK), and cells were treated either with a combination of chemotherapy (FOI) or with 10% DMSO.

Real-time PCR. RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed with TaqMan microRNA reverse transcription kit (Life Technologies, Paisley, UK), and MiR expression assessed by qPCR with TaqMan assay and normalized to that of RNU48 (Life Technologies, Paisley, UK).

Western blot. Immunoblotting was performed as previously described20 using the LiCOR imaging system (Lincoln, Nebraska USA). The primary antibodies from Cell Signalling Technology (London, UK) were used: PARP (#9542), cleaved PARP (#5625), caspase-3 (#9662), cleaved caspase-3 (#9664), pH2A.X (#9718), as well as CLIC3 (AV35262, Sigma-Aldrich, Gillingham, UK) and Beta-Actin (Clone C4, MP Biomedicals, Loughborough, UK).

Luciferase assays. Cells were transfected with 200 ng of CLIC3-pMirTarget or pMirTarget CTRL (Origene, Rockville, MD, USA) with Promofectin Transfection Reagent (Promega, Madison, WI, USA). The luciferase activity was measured 48 h after using the Dual Glo Assay system (Promega, Madison, WI, USA) according to the manufacturer’s protocol in a multwell plate luminometer (Perkin-Elmer, Seer Green, Beaconsfield, UK). Luciferase activity was normalized to that of renilla activity for each transfected well.

MIR1307-KO generation through CRISPR-Cas9. MiaPaca2 cells were transfected with a pair of guide RNA (gRNA) probes (pCAS-GEF1a-FXP, Blue Heron Bio-tech, Bothell, WA, USA) using Lipofectamine 3000 reagent (ThermoFisher Scientific, Waltham Massachusetts, USA). The sequence of the gRNA probes was as follows: gRNA3 5′ GCTGCGTTGTTGATAGAG 3′; gRNA4 5′ AATCTGAGCAGGACCTTGCAG 3′. Forty-eight hours later GFP positive cells were sorted with a BD FACSAria II (BD Biosciences, San Jose, CA, USA). Cells were then enriched for the edited clones by performing serial dilution. The final assessment of the successful genome editing was performed by sequencing and real-time PCR.

Clonogenic assay. Cells were seeded onto Matrigel-coated 24-well plates (200 cells/well) and treated with indicated compounds or vehicle control (DMSO). Values from two-sided t-test are reported.

Generation of stable clones through lentiviral vectors. miRZip lentivector expressing anti-MIR1307-3p (miRZip MIR1307-sh) or scrambled probe (miRZip CTRL) were purchased from System Bioscience (Palo Alto, CA). Can-1 cells were plated in a complete medium. Twenty-four hours later complete medium containing 10 μg/mL of polybrene (Sigma) was added. Lentiviral vector was added and incubated for 24 h before replacing the medium. After 72 h infected cells were selected by puromycin. The presence of GFP was confirmed by fluorescence microscopy (Zeiss AxioObserver Z1 Microscope, Cambridge, UK).

Apoptotic assays. Apoptosis was assessed by using the Caspase-Glo® 3/7, Caspase-Glo® 9, and Caspase-Glo® 8 Assay Systems (Promega, Madison, WI, USA) and Dead Cell Apoptosis Kit with Annexin V FITC (ThermoFisher Scientific, Waltham, Massachusetts, USA), following the manufacturers’ instructions. BD FACSARia II (BD Biosciences, San Jose, CA, USA) was used for flow cytometry. Cells treated with 10 μM staurosporin were used as a positive control. The fluoromethyl ketone peptide Z (LEHD-FMK) was used as caspase 9 inhibitor at a concentration of 20 μM (BD Bioscience, San Diego, CA).

Immunofluorescence. Immunofluorescence staining was performed in a black 96-well plate. Cell medium was removed, and cells were fixed with a solution of PBS containing 4% PFA (ThermoFisher) for 15 min at room temperature. Cells were then washed gently with PBS, and cells were fixed with a solution of PBS containing 0.2% Triton X100 (ThermoFisher) for 15 min at room temperature. Cells were then washed gently with PBS and blocked with a solution of PBS containing 1% BSA for 1 h at room temperature. Blocking was followed by immunostaining with the following antibodies: mouse anti-human pATM (Biolegend, San Diego, USA), mouse anti-human Alexa Fluor 647 H2A.X (ser139) (Biolegend, San Diego USA), rabbit anti-mouse Alexa Fluor 568 (Abcam, Cambridge, UK).

ROS assay. Reactive oxygen species (ROS) generation was assessed by using ROS-Glo® H2O2 Assay Kit (Promega, Madison, WI, USA), following the manufacturers’ instructions. Menadione (50 μM) were used as positive controls. NAC (N-acetyl-cysteine) 10 mM was used as ROS scavenger.

DNA damage assays. A plate-based immunobassay was used to detect the concentration of 8-oxo-dG, a marker of oxidative DNA damage (HT 8-oxo-dG ELISA Kit, R&D Systems, Minneapolis, MN, USA), and The Comet Assay Single Cell Gel Electrophoresis Assay (CN 4230-050-K; R&D Systems, Minneapolis, MN, USA) was used to measure DNA strand breaks following manufacturers’ instructions.

Statistical analyses. Statistical analyses were performed by GraphPad Prism 6 (La Jolla, CA, USA). Results are expressed as mean ± SD, unless indicated otherwise. Groups that were normally distributed were compared with either a two-tailed Student’s t-test (for analysis of two groups) or using a one-way or a two-way ANOVA to compare multiple groups. Non-parametric data were analyzed using a Wilcoxon and a Mann–Whitney U test when comparing two groups. Significance was accepted when p was less than 0.05.

Circulating MiR. Patients with resectable pancreatic carcinoma undergoing FOLIRINOX chemotherapy were enrolled under the research protocol CCR3085 (SSGCC).
Fig. 7 MIR1307 disruption increases chemosensitivity of PDAC xenografts. WT or MIR1307KO MiaPaca2 cells were injected subcutaneously in the flank of NSG mice (N = 16 each) and monitored for growth by caliper. When tumours became visible and measurable (day 21), mice were randomized to be treated with a weekly intraperitoneal vehicle (saline alone) or combination of oxaliplatin (3 mg/kg), fluorouracil (25 mg/kg), and irinotecan (25 mg/kg) for 4 weeks before being sacrificed. A Tumour volume at day 21 was comparable across the groups. Minimum to maximum values are presented. The box indicates the 95% confidence interval with median depicted within the box. Values from two-sided t-test are reported. B Tumour volume data during treatment are shown. Data are normalized to baseline pre-treatment tumour size (day 21). For statistical data please see Table S5. Two-way ANOVA test: p < 0.05. C Excised tumours were weighed before being stored at −80 for analyses. Median values along with minimum to maximum values are shown. Values from two-sided t-test are reported. D Excised tumours were fixed in formalin and included in paraffin. pH2A.X was assessed by IHC and expressed as % of positive cells in each sample. Representative picture and quantification plots are shown. Values from two-sided t-test are reported. E Caspase 3 protein expression was assessed by IHC with a semiquantitative score. Each sample was scored as mild (1+), moderate (2+), and strong (3+) expression. Representative picture along with quantification plots are shown.
that has received approval from the Research Ethics Committee, London. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Baseline whole blood was collected in EDTA-treated tubes; cells were removed by centrifugation for 15 min at 1,500 × g using a refrigerated centrifuge (4 °C). The supernatant was collected and centrifuged for further 10 min at 1,500 × g. RNA was maintained for each sample. Digital droplet PCR (BioRad, Berkeley, CA, USA) was performed according to previously described methods8 using the miRCURY TaqMan probe (Life Technologies, Paisley UK). A no-template control and a negative control for each reverse transcription reaction were included in every assay and at least 10,000 droplets were assessed for each sample. MiR-1307 expression was assessed blinded to clinical data. In the Kaplan–Meier analysis, patients were divided into two groups: low MiR1307 and high MiR1307 according to the median value.

Fig. 8 Circulating MiR1307 predicts benefit from FOLFIRINOX. Plasma was collected from advanced PDAC patients undergoing FOLFIRINOX chemotherapy and subjected to RNA extraction. MiR1307 expression was assessed by droplet digital PCR. Cohort was split according to median MiR1307 expression in low and high MiR1307. Kaplan–Meier curve for correlation with overall survival (OS) is shown.

References
1. Vincent, A. et al. Pancreatic cancer. Lancet 378, 607–620 (2011).
2. Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol. 15, 2403–2413 (1997).
3. Cunningham, D. et al. Phase II randomized comparison of gemcitabine versus gemcitabine plus capcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513–5518 (2009).
4. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
5. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
6. Hosein, P. J. et al. A retrospective study of neoadjuvant FOLFIRINOX in resectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12, 199 (2012).
7. Boone, B. A. et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J. Surg. Oncol. 108, 236–241 (2013).
8. Kadora, B. E. et al. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg. 149, 145–153 (2014).
9. Janssen, Q. P. et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J. Natl Cancer Inst. 111, 782–794 (2019).
10. Gourou-Bourgade, S. et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 31, 23–29 (2013).
11. De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812–1820 (2010).
12. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).
13. Braconi, C. & Patel, T. Non-coding RNAs as therapeutic targets in hepatocellular carcinoma. Curr. Cancer Drug Targets 12, 1073–1080 (2012).
14. Ghidini, M. et al. MicroRNAs as mediators of resistance mechanisms to small-molecule tyrosine kinase inhibitors in solid tumours. Target Oncol. 13, 423–436 (2018).
15. Carotenuto, P. et al. Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expression of CD133+ cells. Hepatology 72, 982–996 (2020).
16. Salati, M. & Bracconi, C. Noncoding RNA in cholangiocarcinoma. Semin. Liver Dis. 39, 13–25 (2019).
17. Bracconi, C. & Patel, T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumours. Hepatology 47, 1807–1809 (2008).
18. Bracconi, C. Hepatitis C virus proteins modulate microRNA expression and chemoresistance in malignant hepatocytes. Clin. Cancer Res. 16, 957–966 (2010).
19. Bracconi, C. et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30, 4750–4766 (2011).
20. Carotenuto, P. et al. Wnt signalling modulates transcribed-ultraconserved RNAs in hepatocellular cancer. J. Natl Cancer Inst. 111, 782–794 (2019).
21. Bloomston, M. et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901–1908 (2007).
22. Jamieson, N. B. et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res. 18, 534–545 (2012).
23. Li, A. et al. Serum miR-1290 as a marker of pancreatic cancer response. Clin. Cancer Res. 19, 5252–5253 (2013).
24. Ma, M. Z. et al. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation, and clinical significance. J. Exp. Clin. Cancer Res. 32, 71 (2013).

25. Frampton, A. E. et al. MicroRNAs cooperatively inhibit a network of tumour suppressor genes to promote pancreatic tumour growth and progression. Gastroenterology 146, 268–77.e18 (2014).

26. Schultz, N. A. et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. Nature Med. 21, 392–404 (2015).

27. He, H., Tian, W., Chen, H. & Jiang, K. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biol. 37, 1599–1609 (2016).

28. Zhou, Y. et al. MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional regulator. Pathol. Res. Pract. 215, 152606 (2019).

29. Moore, M. J. et al. miRNA-target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity. Nat. Commun. 6, 8864 (2015).

30. Gururaja Rao, S., Patel, N. J. & Singh, H. Intracellular chloride channels: novel biomarkers in diseases. Front. Physiol. 11, 96 (2020).

31. Fernández-Sálas, E. et al. miTCLIC/CLIC4, an organellar chloride channel protein, is increased by DNA damage and participates in the apoptotic response to p53. Mol. Cell. Biol. 22, 3610–3620 (2002).

32. van Gisbergen, M. W. et al. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities, and models. Mutat. Res. Rev. Mutat. Res. 764, 16–30 (2015).

33. Catzouloy, T. et al. FOLLIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. Cancer N. Engl. J. Med. 379, 2395–2406 (2018).

34. Ghanem, P. et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized Phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLLIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J. Clin. Oncol. 38, 4505 (2020).

35. de Jesus, V. H. F. et al. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLLIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J. Gastrointest. Oncol. 9, 694–707 (2018).

36. Dreyer, S. B. et al. Pancreatic cancer: from genome discovery to PRECISION-Panc. Clin. Oncol. 32, 5–8 (2020).

37. Sehdev, A. et al. Ceramide and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLLIRINOX. Clin. Cancer Res. 24, 6204–6211 (2018).

38. Palacios, S. et al. DNA damage repair deficiency as a predictive biomarker for FOLLIRINOX efficacy in metastatic pancreatic cancer. J. Gastrointest. Oncol. 10, 1133–1139 (2019).

39. Pea, A., Jamieson, N. B. & Braconi, C. Biology and clinical application of regulatory RNAs in hepatocellular carcinoma. Hepatology https://doi.org/10.1002/hep.31225 (2020).

40. Khan, K. et al. MiR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget 8, 1577–1587 (2017).

41. Al-Momany, A., Li, L., Alexander, R. T. & Ballermann, B. J. Clustered PI(4,5)P2 accumulation and ezrin phosphorylation in response to CLIC5A. J. Cell Sci. 127, 5164–5178 (2014).

42. Singh, H., Cousin, M. A. & Ashley, R. H. Functional reconstitution of mammalian ‘chloride intracellular channels’ CLIC1, CLIC4 and CLIC5 reveals differential regulation by cytoskeleton actin. FEBS J. 274, 6306–6316 (2017).

43. Idelchik, M. D. P. S., Begley, U., Begley, T. J. & Melendez, J. A. Mitochondrial ROS control of cancer. Semin. Cancer Biol. 47, 57–66 (2017).

44. Suh, K. S. et al. CLIC4 is a tumour suppressor for cutaneous squamous cell cancer. Carcinogenesis 33, 986–995 (2012).

45. Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344–1354 (2018).

46. Zarnegar, B. J. et al. iRCLIP platform for efficient characterization of protein-RNA interactions. Nat. Methods 13, 489–492 (2016).

47. Ferracin, M. et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 6, 14545–14555 (2015).

48. Lamps, A. et al. MiR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. J. Hepatol. 56, 1066–1076 (2012).

49. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555–1577 (2010).

50. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).

Acknowledgements C.B. is a current recipient of a Lord Kelvin Adam Smith readership; was previously recipient of an Institute Fellowship, Pancreatic Cancer UK Research Innovation Fund, a Marie Curie Career Integration Grant from the European Union, an Early Diagnosis Award from Pancreatic Cancer Action and a NIHR Royal Marsden/ICR Biomedical Research Centre Flagship Grant, and a Marie Curie Career Integration Grant from the European Union. P.C. is a current recipient of a Marie Skłodowska-Curie Career Re-Integration fellowship funded by AIRC and the European Union’s Horizon 2020 research and innovation programme (Grant agreement No 800924). N.B.J. is a current recipient of a Cancer Research UK Clinician Scientist Fellowship (grant C53570/A25813). A.S. is supported by Associazione Italiana Ricerca Cancro (AIRC 5x1000 n. 12182) and Fondazione Caronno: Oncology Biobank Project “Antonio Sciavi” (prot. 203885/2017). P.W. is supported by CRUK, Wellcome, Chordoma Foundation, Mark Foundation and Isa CRUK Life fellow. We acknowledge funding to the CRUK Cancer Therapeutics Unit at the Institute of Cancer Research (grant G2739/A22897) and findings to CRUK Centre at The Institute of Cancer Research.

Author contributions Study concept and design (C.B.); acquisition of data (P.C., F.A., A.L., C.R., D.Z., M.C.P., A.L., M.F., V.G., R.P., I.S.H., J.C.H., S.X.A., V.M., A.H., V.K., R.U.G., S.H., M.R., F.S., C.V., K.Y. and C.P.); analysis and interpretation of data (C.B. and P.C.); drafting of the manuscript (P.C. and A.L.); critical revision of the manuscript for important intellectual content (C.B.); statistical analysis (C.B. and K.K.); material support (R.B., A.W., S.R., D.W., N.S., A.S., D.R.C., I.C., N.V., D.C., A.B., P.W. and N.J.) obtained funding (C.B., N.V. and D.C.).

Competing interests F.S. has a consultancy role with Bayer; has received research funding from AstraZeneca, Bayer, BMS, Roche; and travel grants from Bayer and Lilly. N.S. has received research funding from AstraZeneca, BMS, Pfizer; honoraria from Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier; travel/accommodation from AstraZeneca, BMS, Eli Lilly, Merck; Roche; and has had advisory roles with Pfizer, AstraZeneca, Servier. D.K.C. received research funding from Celgene, AstraZeneca, MSD and Immodulon, and honoraria from Celgene. D.C. has received funding from Amgen, Sanofi, Merrimack, AstraZeneca, Celgene, MedImmune, Bayer, 45C, Covis, Eli Lilly, Janssen, Merck; and has an advisory role with OVIBIO. M.F. has received grants from Astellas Pharma and QED Therapeutics; and has advisory roles with Astellas Pharma, Tesaro, and Dicaceuts. F.S. received funding from Amal Therapeutics, Bayer, BMS, Dragonfly Therapeutics, Amgen (inst), AstraZeneca (Inst), Bayer (Inst), BMS (Inst), Roche (Inst), Sanofi (Inst), Bayer, Lilly and is Co-Chair EORTC Colon Cancer Task Force. N.V. received honoraria or travel accommodation from Merck Serono, Pfizer, Bayer, Eli Lilly, and Menarini Silicon Biosystems. P.W. advises and received grants from Astex Pharmaceuticals; advises and owns stock in Nextechinvest; is employed and owns stock in Storm Therapeutics; advises CV6 Therapeutics, Black Diamond Therapeutics, and Vividion Therapeutics; received grants from Vernalis and Merck, and owns stock in Chroma Therapeutics. B.C. received honoraria from Incyte. All other authors declare no competing interests.

Additional information Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-27099-6.

Correspondence and requests for materials should be addressed to Chiara Braconi.

Peer review information Nature Communications thanks Gabriel Ichim and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.